Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.35 | 0.17 | 0.31 | -0.25 |
| FCF Yield | -5.30% | -10.85% | -9.04% | -5.06% |
| EV / EBITDA | -27.20 | -10.97 | -14.85 | -14.84 |
| Quality | ||||
| ROIC | -12.46% | -13.79% | -15.32% | -15.20% |
| Gross Margin | 95.42% | 96.63% | 95.58% | 89.24% |
| Cash Conversion Ratio | 1.16 | 1.22 | 1.12 | 0.61 |
| Growth | ||||
| Revenue 3-Year CAGR | 4,813,734.51% | 4,275,842.82% | 3,522,797.49% | 2,871,521.74% |
| Free Cash Flow Growth | 19.51% | 7.74% | -65.82% | 7.92% |
| Safety | ||||
| Net Debt / EBITDA | -3.98 | 1.67 | -2.29 | -2.14 |
| Interest Coverage | -6.93 | -8.83 | -10.41 | -20.05 |
| Efficiency | ||||
| Inventory Turnover | 0.08 | 0.07 | 0.19 | 0.00 |
| Cash Conversion Cycle | 563.38 | 112.87 | -476.82 | 162.55 |